Mivelsiran: Phase 1 Study
Mivelsiran: Phase 1 Study
The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.
The safety and efficacy of mivelsiran are currently being investigated in clinical studies and have not been evaluated by the FDA or any health authority.
If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.
Summary
Mivelsiran targets intracellular and extracellular APP production in the CNS, upstream of amyloidogenic processing, through reduction of APP mRNA. The investigational hypothesis for mivelsiran suggests that the reduction of APP production causes the downstream Aβ protein species to be reduced.1 The safety, tolerability, PD, and PK of mivelsiran in patients with EOAD are being evaluated in an ongoing randomized, double-blind, placebo-controlled, 2-part Phase 1 study (NCT05231785).1,2 |
Aβ = amyloid beta; Aβ40 = amyloid beta peptide length 40 amino acids; Aβ42 = amyloid beta peptide length 42 amino acids; AD = Alzheimer’s disease; AE = adverse event; APOE = apolipoprotein E; APP = amyloid precursor protein; ARIA = amyloid‑related imaging abnormality; ARIA‑E = amyloid‑related imaging abnormality presenting as edema; BL = baseline; BMI = body mass index; CAA = cerebral amyloid angiopathy; CDR = Clinical Dementia Rating; CNS = central nervous system; CSF = cerebrospinal fluid; EOAD = early onset Alzheimer’s disease; IT = intrathecal; LP = lumbar puncture; M = month; MAD = multiple ascending dose; MCI = mild cognitive impairment; MMSE = Mini Mental State Examination; NfL = neurofilament light chain protein; PBO = placebo; PD = pharmacodynamics; PET = positron emission tomography; PK = pharmacokinetics; PY = patient-years; Q6M = every 6 months; RNAi = ribonucleic acid interference; SAD = single ascending dose; sAPP = soluble amyloid precursor protein; SD = standard deviation; SE = standard error; ULN = upper limit of normal.
Index
Study Design – Patient Demographics & Baseline Characteristics – Safety Results – Pharmacodynamic Results – Exploratory Results – References
The Phase 1 study (NCT05231785) is an ongoing, global, randomized, double-blind, placebo-controlled, 2‑part study designed to evaluate the safety, tolerability, PD, and PK of mivelsiran in patients with EOAD. Part A of the study is a double-blind, single-ascending dose study, while Part B of the study is an open-label multi-dose study of mivelsiran.1,2
In Part A, study participants (N=36) were dosed with a single dose of mivelsiran or placebo via IT administration. Following completion of Part A, eligible patients were sequentially assigned to Part B cohorts (Figure 1).2
Figure 1. Phase 1 Study Design of Mivelsiran in EOAD.2
Abbreviations: AD = Alzheimer’s disease; Aβ = amyloid-beta; Aβ40 = Aβ peptide length 40 amino acids; Aβ42 = Aβ peptide length 42 amino acids; BL = baseline; CDR = Clinical Dementia Rating; CSF = cerebrospinal fluid; EOAD = early onset Alzheimer’s disease; IT = intrathecal; M = month; MAD = multiple ascending dose; MCI = mild cognitive impairment; MMSE = Mini Mental State Examination; NfL = neurofilament light chain protein; PBO = placebo; PD = pharmacodynamics; PET = positron emission tomography; Q6M = every 6 months; SAD = single ascending dose; sAPP = soluble amyloid precursor protein.
aPatients are determined to have completed Part A at or after Month 6 when sAPPα and sAPPβ levels have returned to ≥75% of the patient's Day 1 sAPPα and sAPPβ level for two consecutive visits or at Month 12, whichever is earlier.
bAcceptable safety profile in Part A, and ≥25% reduction in CSF sAPPα and sAPPβ in ≥3 patients.
cEligible patients from Part A are sequentially assigned to Part B cohorts based on the order of Part A study completion.
dIn period 1, up to four dosing regimens will be evaluated; in period 2, cohorts are consolidated into up to two dosing regimens at the Month 18 visit.
From Cohen et al.2
For each part separately, the primary endpoint assessed the safety and tolerability of mivelsiran as measured by the frequency of AEs. The secondary endpoints of the study included the evaluation of the PK profile of mivelsiran in CSF and plasma, and the change from baseline in CSF levels of sAPPα and sAPPβ. Exploratory endpoints included an assessment of biomarkers of disease progression (change from baseline in CSF levels of Aβ42, Aβ40, and NfL). Patients with mild cognitive impairment or mild dementia due to EOAD confirmed by CSF biomarkers or Aβ PET, and symptom onset before the age of 65 were included in the study. There were no exclusions in the study protocol for CAA, ARIA, or APOE genotype.1–3
Patient Demographics & Baseline Characteristics
The patient demographics and baseline characteristics of patients enrolled in Part A and Part B are presented in Table 1 as of a data cutoff of May 21, 2026.3
Table 1. Patient Demographics and Baseline Characteristics Through Month 30 of Open-Label MAD.3
Baseline Characteristic | Double-blind SAD | Open-label MADa | |
Placebo (N=15) | Mivelsiran (N=38) | Mivelsiran Q6M (N=57) | |
Age, years, mean (SD) | 61.1 (4.9) | 61.9 (5.4) | 62.1 (6.0) |
Male, n (%) | 7 (46.7) | 22 (57.9) | 34 (59.6) |
Race, n (%) |
|
|
|
White | 13 (86.7) | 34 (89.5) | 49 (86.0) |
Asian | 2 (13.3) | 2 (5.3) | 5 (8.8) |
Black/African American | 0 | 1 (2.6) | 1 (1.8) |
Unknown/Other | 0 | 1 (2.6) | 2 (3.5) |
CDR® global score, n (%) |
|
|
|
0.0 | 0 | 1 (2.6) | 2 (3.5) |
0.5 | 10 (66.7) | 32 (84.2) | 33 (57.9) |
1.0 | 5 (33.3) | 5 (13.2) | 20 (35.1) |
2.0 | 0 | 0 | 1 (1.8) |
Missing | 0 | 0 | 1 (1.8) |
MMSE score, mean (SD) | 24.1 (2.9) | 25.4 (3.0) | 23.7 (3.7) |
Centiloid PET, CL, mean (SD) | 106.41 (24.30) | 101.09 (38.32) | 97.03 (32.79) |
APOE4 genotype, n (%) |
|
|
|
Carrierb | 9 (60.0) | 26 (68.4) | 35 (61.4) |
Carrier homozygous | 4 (26.7) | 7 (18.4) | 13 (22.8) |
Missing genotype status | 0 | 1 (2.6) | 2 (3.5) |
ARIA status, n (%) |
|
|
|
ARIA-H, present | 1 (6.7) | 2 (5.3) | 6 (10.5) |
ARIA-E, present | 0 | 0 | 0 |
Missing ARIA statusc | 1 (6.7) | 1 (2.6) | 0 |
Abbreviations: APOE4 = apolipoprotein E ε4 allele; ARIA = amyloid-related imaging abnormalities; ARIA-E = amyloid-related imaging abnormalities-edema/effusion; ARIA-H = amyloid-related imaging abnormalities-hemorrhage/hemosiderin; CDR = Clinical Dementia Rating; EOAD = early-onset Alzheimer’s disease; MAD = multiple ascending dose; MMSE = Mini Mental State Examination; MRI = magnetic resonance imaging; PET = positron emission tomography; Q6M = every 6 months; SAD = single ascending dose; SD = standard deviation. aMAD part includes patients from SAD part or their replacements. bAt least one ε4 allele. cOne patient receiving placebo and one patient receiving mivelsiran in the SAD study part had no MRI scan at baseline so were considered to be missing ARIA data at baseline. Data shown as of May 21, 2026. | |||
As of May 21, 2026 (through Month 30 of the open-label MAD), there were 63 unique patients: 47 who participated in both Part A and Part B of the study, 6 from Part A only, and 10 replacement patients in Part B. Of these 63 patients, 40 patients (63.5%) were APOE4 carriers, of which 14 patients (22.2%) were APOE4 homozygous. Of the 63 unique patients 6 patients (9.5%) had ARIA-H at study baseline, with cerebral microhemorrhages detected prior to study drug exposure. One of the 63 patients (1.6%) had superficial siderosis at baseline.3
Safety Data Through Month 18
The safety and tolerability of mivelsiran was monitored throughout the study and in the follow-up period as a primary endpoint. A safety summary of AEs across cohorts in Part A and Part B through Month 18 (data cutoff of May 15, 2025) of the open-label MAD is shown in Table 2. The majority of AEs were nonserious, mild or moderate, and considered not related to study drug.2
Table 2. Summary of Adverse Events in Parts A & B by Cohort Through Month 18 of Open-Label MAD.2
Events, n (%) | Part A: SAD (N=53) | Part B: MAD (N=22) | ||||||||
25 mg (n=4) PY=4.5 | 35 mg (n=6) PY=6.4 | 50 mg (n=6) PY=6.2 | 75 mg (n=10) PY=11.6 | 100 mg (n=6) PY=7.3 | 150 mg (n=6) PY=5.6 | Placebo (n=15) PY=11.9 | 50 mg (n=10) PY=14.6 | 75 mg (n=12) PY=10.6 | ||
Duration on study months, mean (SD) | 13.6 (1.5) | 12.8 (2.8) | 12.4 (4.5) | 13.9 (2.5) | 14.7 (1.3) | 11.1 (1.2) | 9.5 (3.3) | 17.6 (2.1) | 10.7 (3.0) | |
At least 1 AE | 4 (100.0) | 6 (100.0) | 6 (100.0) | 10 (100.0) | 6 (100.0) | 6 (100.0) | 14 (93.3) | 10 (100.0) | 10 (83.3) | |
Related to study drug | 0 | 0 | 1 (16.7) | 2 (20.0) | 0 | 2 (33.3) | 1 (6.7) | 0 | 1 (8.3) | |
Related to LP | 3 (75.0) | 5 (83.3) | 5 (83.3) | 5 (50.0) | 6 (100.0) | 2 (33.3) | 10 (66.7) | 7 (70.0) | 5 (41.7) | |
At least 1 severe AE | 0 | 0 | 0 | 1 (10.0)a | 0 | 1 (16.7) | 1 (6.7) | 0 | 0 | |
At least 1 serious AE | 0 | 0 | 0 | 1 (10.0)a | 0 | 1 (16.7) | 0 | 0 | 1 (8.3) | |
Death | 0 | 0 | 0 | 1 (10.0)a | 0 | 0 | 0 | 0 | 0 | |
Abbreviations: AE = adverse event; LP = lumbar puncture; MAD = multiple ascending dose; PY = patient years; SAD = single ascending dose; SD = standard deviation. aOne patient had one event of acute pancreatitis on Day 277 after dosing that was fatal on Day 288. The event was classified as serious, severe, and not related to study drug/LP. Data shown as of May 15, 2025. | ||||||||||
Safety Data Through Month 30
As of a data cutoff of May 21, 2026 through Month 30 of the open-label MAD, there were no serious or severe AEs that were considered related to study drug. The most common AEs were procedural pain and procedural headache. CSF safety labs showed no significant elevations of CSF total protein or white blood cells.3
Rates of ARIA from Interim Analysis Through Month 30
An analysis describing the rates of ARIA through Month 30 of the open-label MAD by treatment group is provided in Table 3 (data cutoff of May 21, 2026).3
Table 3. ARIA Rates by Treatment Group Through Month 30 of Open-Label MAD.3,a
| Double-blind SAD | Open-label MADb | |
Placebo | Mivelsiran | Mivelsiran Q6M | |
New/worsened, post-baseline ARIA-H, n (%) | 1 (6.7)c | 2 (5.3) | 4 (7.0)d |
Site investigator-reported ARIA-H AE, n (%)e | 1 (6.7) | 2 (5.3)f | 3 (5.3)f |
Abbreviations: AE = adverse event; APOE4 = apolipoprotein E ε4 allele; ARIA = amyloid-related imaging abnormalities; ARIA-E = amyloid-related imaging abnormalities-edema/effusion; ARIA-H = amyloid-related imaging abnormalities-hemorrhage/hemosiderin; MAD = multiple ascending dose; MRI = magnetic resonance imaging; Q6M = every 6 months; SAD = single ascending dose; aIncidence was calculated by dividing the number of new cases of ARIA that developed post baseline by the total population. bMAD part includes patients from SAD part or their replacements. cPatient was missing baseline MRI sequences required for ARIA adjudication; for patients with missing baseline data, ARIA were assumed to be non-present at baseline. dOne patient also had worsened ARIA-H in the SAD part of the study. dAEs are reported by principal investigators at their discretion and includes patients with stable ARIA from baseline. fOne patient had baseline ARIA-H. Data shown as of May 21, 2026. | |||
Blinded radiologists evaluated MRIs for ARIA-E and ARIA-H. There were no patients with ARIA-E based on MRI data. There were 8 total patients with ARIA-H: 2 patients with stable ARIA-H from baseline with APOE4/4 and APOE3/4 genotype and 6 patients with new or worsened post-baseline ARIA-H, 3 of whom had APOE4/4 genotype (Table 4).3
Table 4. ARIA-H in Patients Receiving Mivelsiran or Placebo Through Month 30 of Open-Label MAD.3
ARIA-H | |
SAD |
|
Placebo | Microhemorrhage |
Mivelsiran 75 mg | Microhemorrhage |
Mivelsiran 100 mg | Microhemorrhage and superficial siderosis |
MAD |
|
Mivelsiran 75 mg | Superficial siderosis |
Mivelsiran 75 mg | Microhemorrhage |
Mivelsiran higher dose | Microhemorrhage |
Mivelsiran higher dose | Microhemorrhage and superficial siderosis |
Abbreviations: ARIA-H= amyloid-related imaging abnormalities-hemorrhage/hemosiderin; MAD = multiple ascending dose; SAD = single ascending dose. | |
There were no reports of ARIA-E based on AE data. ARIA-H AEs were reported in 6 patients, totaling 8 events. All ARIA-H AEs were reported as mild in severity. No reports were deemed related to treatment by the investigators and no symptoms associated with ARIA-H AEs were reported.3
CSF sAPPβ
In an interim analysis of Part A (25 mg, 35 mg, 50 mg, and 75 mg cohorts) through Month 12 of the double-blind SAD, CSF sAPPβ levels were reduced following a single dose of mivelsiran above 25 mg. At Month 1 following a single dose of mivelsiran 75 mg, the peak mean reduction from baseline in sAPPβ was 73.5%. Dose-dependent reductions were sustained through Month 6; reductions were observed through Month 12 with the single 50 or 75 mg doses.1 A single dose of mivelsiran 150 mg resulted in a peak mean reduction from baseline in sAPPβ of 85% at Month 1 and 75% at Month 6 (Figure 2).2
Figure 2. Mean Percent Change from Baseline in CSF sAPPβ After Single Dose of Mivelsiran During Double-Blind SAD.2
Abbreviations: CSF = cerebrospinal fluid; D = day; M, month; sAPP = soluble amyloid precursor protein; SAD = single ascending dose; SE = standard error.
Data shown as of May 15, 2025. Time points with an n of <3 are not plotted.
Placebo: n=14 (D2), n= 13 (D15, M1–3, M6), n=12 (M4), n=11 (M5), n=3 (M8); mivelsiran 25 mg: n=4 (M6), n=3 (M8); mivelsiran 35 mg: n=5 (M8, M10), n=4 (M12); mivelsiran 50 mg: n=5 (M2, M4–12), mivelsiran 75 mg: n=9 (D2), n=8 (M10, M12); mivelsiran 100 mg: n=5 (M2, M4, M8, M12); mivelsiran 150 mg: n=5 (M1, M2, M4–6, M10), n=4 (M3).
From Cohen et al.2
Figure 3. Mean Percent Change from Baseline in CSF sAPPβ With Mivelsiran Q6M Dosing During Open-Label MAD.3
Abbreviations: CSF = cerebrospinal fluid; MAD = multiple ascending dose; Q6M = every 6 months; sAPP = soluble amyloid precursor protein; SE = standard error.
Data shown as of May 21, 2026. Time points with an n of <3 are not plotted.
From Parikh et al.3
Exploratory Results
CSF Aβ42 and Aβ40
In Part A during the double-blind SAD, reductions in CSF Aβ42 and Aβ40 were observed with all doses at Day 15. In the 150 mg cohort, the peak mean (SE) reductions from baseline in CSF Aβ42 and Aβ40 were 61% (8) and 79% (5), respectively, at Month 2. Following a single dose of mivelsiran over 25 mg, mean reductions in Aβ42 over 25% and in Aβ40 over 30% were sustained to Month 6.2
In Part B during the open-label MAD through Month 12, the change from baseline in CSF Aβ42 and Aβ40 with multiple doses of mivelsiran is presented in Figure 4.2 During the open-label MAD through Month 30, the mean maximum reduction in the highest dose group for Aβ42 was 70.2%.2,3
Figure 4. Mean Percent Change from Baseline in CSF Aβ42 and Aβ40 After Multiple Doses of Mivelsiran at up to 12 Months During Open-Label MAD.2
Abbreviations: Aβ = amyloid beta; Aβ40 = Aβ peptide length 40 amino acids; Aβ42 = Aβ peptide length 42 amino acids; CSF = cerebrospinal fluid; SE = standard error.
Data shown as of May 15, 2025. Time points with an n of <3 are not plotted.
From Cohen et al.2
Data shown as of May 15, 2025. Time points with an n of <3 are not plotted.
From Cohen et al.2
Updated 06 October 2026
|
|
|
MED-ALL-APP-2300003 4.0 Approved through Oct 2028 |
